Skip to main content

Table 1 Clinical characteristics of different groups of patients included in the study

From: Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential

 

C (n = 15)

DLP (n = 14)

T2D (n = 17)

T2D-DLP (n = 17)

Anthropometric data

 Gender (F/M)

3F/2 M

3F/1 M

2F/5 M

8F/9 M

 Age (years)

43 ± 8

60 ± 11

64 1 ± 13

58 ± 9

 Onset of disease (years)

0

0

1 → 10

1 → 14

 BMI (kg/m2)

29 ± 7

35 ± 2

29 ± 4

32 ± 5

Metabolic waste products

 Serum urea (mg/dL)

24 ± 6

32 ± 8

35 ± 14

33 ± 10

 Serum creatinine (mg/dL)

1 ± 0

1 ± 0

1 ± 0

1 ± 0

 Serum uric acid (mg/dL)

5 ± 2

7 ± 2

5 ± 2

5 ± 1

 Serum hemoglobin (g/dL)

14 ± 1

15 ± 1

15 ± 1

14 ± 1

 Erythrocytes (mm3)

5,040,000 ± 183,847

5,210,000 ± 226,274

5,152,000 ± 388,361

4,913,333 ± 795,831

 Platelets (mm3)

233,666 ± 68,233

244,375 ± 164,421

193,714 ± 52,392

253,316 ± 55,037

 Leucocytes (mm3)

6496 ± 2409

10,452 ± 4060

7634 ± 2779

8399 ± 2302

 Monocytes (mm3)

623 ± 68

713 ± 396

664 ± 75

755 ± 160

Metabolic parameters

 Fasting plasma glucose (mg/dL)

80 ± 10

88 ± 9

152 ± 48a

144 ± 28a

 HbA1c (%)

5 ± 0.6

6 ± 0.8

7 ± 1.4a

7 ± 2ª

 Serum triglycerides (mg/dL)

104 ± 27

212 ± 17a

125 ± 11

167 ± 11a,b

 Serum cholesterol (mg/dL)

200 ± 32

204 ± 71

171 ± 39

162 ± 48

 HDL cholesterol (mg/dL)

54 ± 19

38 ± 7

44 ± 14

40 ± 5

 LDL cholesterol (mg/dL)

104 ± 17

127 ± 27

101 ± 35

129 ± 29

 TGO (UI/L)

22 ± 10

20 ± 5

19 ± 18

22 ± 12

 TGP (UI/L)

24 ± 13

23 ± 17

22 ± 13

26 ± 15

Heart function

 Systolic blood pressure (mmHg)

113 ± 10

152 ± 19a

132 ± 10ª

133 ± 15

 Diastolic blood pressure (mmHg)

68 ± 10

96 ± 11a

81 ± 13

76 ± 11

 Heart rate (bpm)

71 ± 9

93 ± 8

94 ± 11

84 ± 10

  1. Data presented as mean ± SD (one-way ANOVA and Bonferonni)
  2. C control, DLP dyslipidemia, T2D type 2 diabetes, T2D-DLP diabetic dyslipidemia
  3. ap < 0.05 vs C
  4. bp < 0.05 vs T2D